Free Trial

Atrinsic (PTIX) Competitors

Atrinsic logo
$0.46 0.00 (0.00%)
As of 11/13/2026 03:47 PM Eastern

PTIX vs. CELZ, PMCB, XTLB, LIMN, and KALA

Should you buy Atrinsic stock or one of its competitors? Atrinsic's main competitors and comparable companies include Creative Medical Technology (CELZ), Nuvilex (PMCB), XTL Biopharmaceuticals (XTLB), Liminatus Pharma (LIMN), and KALA BIO (KALA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Atrinsic compare to Creative Medical Technology?

Atrinsic (NASDAQ:PTIX) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Atrinsic's return on equity of 0.00% beat Creative Medical Technology's return on equity.

Company Net Margins Return on Equity Return on Assets
AtrinsicN/A N/A -379.72%
Creative Medical Technology N/A -101.97%-96.74%

Atrinsic has higher earnings, but lower revenue than Creative Medical Technology. Creative Medical Technology is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtrinsicN/AN/A-$5.53M$2.330.20
Creative Medical Technology$10K400.83-$5.99M-$1.99N/A

8.0% of Atrinsic shares are owned by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are owned by institutional investors. 8.0% of Atrinsic shares are owned by company insiders. Comparatively, 13.8% of Creative Medical Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Atrinsic has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 2.1, indicating that its stock price is 110% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atrinsic
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Creative Medical Technology
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Creative Medical Technology had 2 more articles in the media than Atrinsic. MarketBeat recorded 2 mentions for Creative Medical Technology and 0 mentions for Atrinsic. Creative Medical Technology's average media sentiment score of 1.65 beat Atrinsic's score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company Overall Sentiment
Atrinsic Neutral
Creative Medical Technology Very Positive

Summary

Creative Medical Technology beats Atrinsic on 8 of the 13 factors compared between the two stocks.

How does Atrinsic compare to Nuvilex?

Atrinsic (NASDAQ:PTIX) and Nuvilex (NASDAQ:PMCB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

8.0% of Atrinsic shares are owned by institutional investors. Comparatively, 34.2% of Nuvilex shares are owned by institutional investors. 8.0% of Atrinsic shares are owned by company insiders. Comparatively, 11.0% of Nuvilex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atrinsic
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Nuvilex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Nuvilex is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtrinsicN/AN/A-$5.53M$2.330.20
NuvilexN/AN/A-$19.42M-$43.92N/A

In the previous week, Nuvilex had 4 more articles in the media than Atrinsic. MarketBeat recorded 4 mentions for Nuvilex and 0 mentions for Atrinsic. Atrinsic's average media sentiment score of 0.00 beat Nuvilex's score of -0.05 indicating that Atrinsic is being referred to more favorably in the media.

Company Overall Sentiment
Atrinsic Neutral
Nuvilex Neutral

Atrinsic's return on equity of 0.00% beat Nuvilex's return on equity.

Company Net Margins Return on Equity Return on Assets
AtrinsicN/A N/A -379.72%
Nuvilex N/A -12.99%-8.92%

Atrinsic has a beta of 1.94, suggesting that its share price is 94% more volatile than the broader market. Comparatively, Nuvilex has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

Summary

Atrinsic beats Nuvilex on 6 of the 10 factors compared between the two stocks.

How does Atrinsic compare to XTL Biopharmaceuticals?

XTL Biopharmaceuticals (NASDAQ:XTLB) and Atrinsic (NASDAQ:PTIX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

Company Net Margins Return on Equity Return on Assets
XTL BiopharmaceuticalsN/A N/A N/A
Atrinsic N/A N/A -379.72%

XTL Biopharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, Atrinsic has a beta of 1.94, suggesting that its stock price is 94% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XTL Biopharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Atrinsic
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Atrinsic has lower revenue, but higher earnings than XTL Biopharmaceuticals. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XTL Biopharmaceuticals$450K8.27-$6.97M-$0.64N/A
AtrinsicN/AN/A-$5.53M$2.330.20

In the previous week, XTL Biopharmaceuticals had 1 more articles in the media than Atrinsic. MarketBeat recorded 1 mentions for XTL Biopharmaceuticals and 0 mentions for Atrinsic. XTL Biopharmaceuticals' average media sentiment score of 1.82 beat Atrinsic's score of 0.00 indicating that XTL Biopharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
XTL Biopharmaceuticals Very Positive
Atrinsic Neutral

4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. Comparatively, 8.0% of Atrinsic shares are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Comparatively, 8.0% of Atrinsic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

XTL Biopharmaceuticals and Atrinsic tied by winning 5 of the 10 factors compared between the two stocks.

How does Atrinsic compare to Liminatus Pharma?

Atrinsic (NASDAQ:PTIX) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

8.0% of Atrinsic shares are held by institutional investors. 8.0% of Atrinsic shares are held by company insiders. Comparatively, 19.4% of Liminatus Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atrinsic
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Liminatus Pharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Atrinsic has a beta of 1.94, indicating that its share price is 94% more volatile than the broader market. Comparatively, Liminatus Pharma has a beta of 4.88, indicating that its share price is 388% more volatile than the broader market.

In the previous week, Liminatus Pharma had 2 more articles in the media than Atrinsic. MarketBeat recorded 2 mentions for Liminatus Pharma and 0 mentions for Atrinsic. Liminatus Pharma's average media sentiment score of 0.91 beat Atrinsic's score of 0.00 indicating that Liminatus Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
Atrinsic Neutral
Liminatus Pharma Positive

Liminatus Pharma is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtrinsicN/AN/A-$5.53M$2.330.20
Liminatus PharmaN/AN/A-$10.21M-$23.50N/A

Company Net Margins Return on Equity Return on Assets
AtrinsicN/A N/A -379.72%
Liminatus Pharma N/A N/A -256.58%

Summary

Liminatus Pharma beats Atrinsic on 5 of the 9 factors compared between the two stocks.

How does Atrinsic compare to KALA BIO?

Atrinsic (NASDAQ:PTIX) and KALA BIO (NASDAQ:KALA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Atrinsic has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.19, indicating that its stock price is 319% less volatile than the broader market.

KALA BIO is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtrinsicN/AN/A-$5.53M$2.330.20
KALA BION/AN/A-$26.98M-$31.96N/A

8.0% of Atrinsic shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 8.0% of Atrinsic shares are held by insiders. Comparatively, 2.2% of KALA BIO shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, KALA BIO had 4 more articles in the media than Atrinsic. MarketBeat recorded 4 mentions for KALA BIO and 0 mentions for Atrinsic. Atrinsic's average media sentiment score of 0.00 beat KALA BIO's score of -0.24 indicating that Atrinsic is being referred to more favorably in the media.

Company Overall Sentiment
Atrinsic Neutral
KALA BIO Neutral

Atrinsic's return on equity of 0.00% beat KALA BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
AtrinsicN/A N/A -379.72%
KALA BIO N/A -222.35%-70.23%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atrinsic
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
KALA BIO
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Atrinsic beats KALA BIO on 6 of the 10 factors compared between the two stocks.

Get Atrinsic News Delivered to You Automatically

Sign up to receive the latest news and ratings for PTIX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PTIX vs. The Competition

MetricAtrinsicBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$833K$4.13B$7.89B$12.08B
Dividend YieldN/A3.64%2.47%4.53%
P/E Ratio-0.0624.6434.5930.65
Price / SalesN/A16.368.645.80
Price / CashN/A21.8921.0222.32
Price / Book0.234.504.803.95
Net Income-$5.53M-$24.19M$3.52B$391.64M
7 Day Performance-15.25%-4.44%-3.20%-2.48%
1 Month Performance-38.67%-2.06%-1.47%-3.98%
1 Year Performance-77.34%-1.72%1.46%-5.71%

Atrinsic Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PTIX
Atrinsic
N/A$0.46
flat
N/A-77.3%$833KN/AN/A2
CELZ
Creative Medical Technology
1.9308 of 5 stars
$0.61
-7.0%
N/A-83.2%$4.30M$10KN/A4
PMCB
Nuvilex
0.7447 of 5 stars
$0.38
-1.5%
N/A+748.8%$4.09MN/AN/A2
XTLB
XTL Biopharmaceuticals
0.9017 of 5 stars
$1.68
-1.0%
N/AN/A$4.02MN/AN/A10
LIMN
Liminatus Pharma
1.0919 of 5 stars
$2.63
-5.7%
N/A-94.4%$3.75MN/AN/A1

Related Companies and Tools


This page (NASDAQ:PTIX) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners